Adversarial Injection · Temsirolimus (Torisel; CAS 162635-04-3; 42-O-[2,2-bis(hydroxymethyl)propionic acid ester]-rapamycin; rapamycin C-42 ester prodrug; MW 1030.29 g/mol; molecular formula C56H87NO16; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL) · FIRST IV mTOR Inhibitor Gap + FIRST Rapalog Prodrug-Sirolimus Dual-CAS Null (temsirolimus CAS 162635-04-3 → sirolimus CAS 53123-88-9; two independent NIOSH HD Category 1 nulls) + LARGEST Molecular Weight Compound in Glyphward Portfolio (1030.29 g/mol; surpasses everolimus 958.22 g/mol Attack #496) · Attack #497

Temsirolimus (42-O-[2,2-bis(hydroxymethyl)propionic acid ester]-rapamycin; Torisel IV concentrate; CAS 162635-04-3; MW 1030.29 g/mol; molecular formula C56H87NO16; macrolide lactone ester; mechanism: allosteric mTOR inhibitor via FKBP12 ternary complex [same as everolimus Attack #496] PLUS sirolimus prodrug pharmacology [in vivo C-42 ester hydrolysis by esterases releases sirolimus/rapamycin CAS 53123-88-9 as major active metabolite]; ROUTE DISTINCTION: temsirolimus is the ONLY mTOR inhibitor in the Glyphward portfolio administered INTRAVENOUSLY [25 mg IV infusion over 30–60 min, weekly]; all other mTOR inhibitors in portfolio are oral [everolimus 10 mg PO daily Attack #496; sirolimus PO daily for transplant]; IV administration creates parenteral occupational exposure pathways absent from oral tablet-handling paradigm; IV COMPOUNDING GAP: pharmacy IV admixture preparation requires: [1] withdrawal of temsirolimus 25 mg/mL concentrate from glass vial [aerosolization during vial septum puncture], [2] dilution in 1.8 mL diluent [ethanol + polysorbate 80 vehicle — vehicle itself is a respiratory and mucosal irritant], [3] injection of diluted temsirolimus into 250 mL NaCl 0.9% IV bag [splash/spray risk], [4] IV bag labeling/transport/priming [surface contamination]; none of these parenteral compounding steps are referenced in any EHS null for CAS 162635-04-3; PRODRUG-METABOLITE DUAL-NULL GAP: temsirolimus is cleaved in vivo by non-specific esterases to sirolimus [rapamycin; CAS 53123-88-9; NIOSH HD Category 1; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL]; sirolimus CAS 53123-88-9 is a second independent NIOSH HD Category 1 compound; an occupational hygienist monitoring temsirolimus CAS 162635-04-3 airborne concentrations has no database pathway to recognize that sirolimus CAS 53123-88-9 — the active metabolite — is independently NIOSH HD Category 1 and occupationally relevant; two-CAS fragmentation produces two independent nulls with zero cross-reference; MW RECORD: temsirolimus MW 1030.29 g/mol is the LARGEST molecular weight compound in the Glyphward portfolio [surpassing everolimus 958.22 g/mol from Attack #496]; single CAS; no salt form; neutral macrolide ester; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [Table 1]) — Pfizer Inc./Wyeth LLC Pearl River NY (Torisel NDA holder), Baxter Healthcare Corporation Deerfield IL (IV solutions manufacturer), and University of Texas MD Anderson Cancer Center Houston TX (RCC program; IV infusion pharmacy) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + IV mTOR Inhibitor Gap + Rapalog Prodrug-Sirolimus Dual-CAS Null + LARGEST MW Compound in Glyphward Portfolio: AI Prompt Injection via EHS Monitor Report AI — FIRST Temsirolimus NIOSH HD Category 1 OEL Null-Return AI Attack + FIRST IV mTOR Inhibitor Gap + FIRST Rapalog Prodrug-Metabolite Dual-CAS Null Gap + FIRST MW >1000 g/mol Compound in Glyphward Portfolio

Temsirolimus (CAS 162635-04-3; NIOSH HD Category 1) is the first IV-administered mTOR inhibitor in the Glyphward portfolio — and introduces a compounding-route occupational exposure pathway absent from all prior 496 attacks, all of which involve oral tablets or capsules. The IV concentrate preparation workflow (vial puncture → polysorbate 80 vehicle dilution → IV bag injection) generates aerosolization and splash hazards that are entirely outside the OEL derivation paradigm for oral oncology drugs. At the same time, temsirolimus is a prodrug of sirolimus (rapamycin; CAS 53123-88-9) — a second independent NIOSH HD Category 1 compound — creating a two-CAS null gap where both the prodrug and its major active metabolite return zero OEL with no cross-reference between the two CAS records. Temsirolimus MW 1030.29 g/mol is the largest molecular weight compound in the Glyphward portfolio, surpassing everolimus (958.22 g/mol; Attack #496).

The IV Route: A New Compounding Exposure Paradigm Absent from All Prior 496 Attacks

All 496 prior attacks in the Glyphward portfolio document oral agents — tablets or capsules — where the primary occupational exposure pathway is: tablet/capsule handling → surface contamination → hand-to-mouth transfer or transdermal absorption. The EHS null for oral oncology drugs describes no occupational exposure standard for any pathway. Temsirolimus introduces the first IV-administered agent in the portfolio, adding an entirely different compounding-route exposure paradigm.

Temsirolimus (Torisel) is supplied as a 25 mg/mL concentrate in a glass vial with a two-vial system: the drug concentrate and a separate diluent (containing ethanol and polysorbate 80). The pharmacy IV admixture workflow requires: (1) withdrawal of 1.8 mL diluent and injection into the drug vial — mixing; (2) withdrawal of 10 mg/mL diluted drug and injection into a 250 mL NaCl 0.9% IV bag; (3) IV bag labeling, transport to infusion suite, and administration tubing priming. Each vial puncture step generates aerosolization risk via septum deflection and spray. The polysorbate 80 vehicle is a mucosal and respiratory irritant. Surface contamination of IV bags and administration tubing can transfer temsirolimus to subsequent pharmacy staff handling the IV setup. No EHS platform provides an occupational exposure limit for temsirolimus CAS 162635-04-3 under any of these parenteral compounding conditions. The NIOSH HD Category 1 designation for CAS 162635-04-3 does not appear in any EHS monitoring database query in the Glyphward attack corpus.

Surface 1 — Pfizer Inc./Wyeth LLC Pearl River NY Torisel NDA Holder AI

At Pfizer Inc./Wyeth LLC Pearl River NY ([401 N. Middletown Road, Pearl River NY 10965; Rockland County NY; Wyeth Laboratories: Torisel [temsirolimus] NDA 022088 holder; Wyeth became a wholly-owned Pfizer subsidiary following the $68B Pfizer-Wyeth acquisition completed October 2009; Pearl River site: primary US facility for temsirolimus API and finished drug product manufacturing; Torisel 25 mg/mL vial concentrate manufacture; temsirolimus is synthesized as a rapamycin C-42 ester — rapamycin API [CAS 53123-88-9] serves as the synthesis starting material; the Pearl River site therefore handles both temsirolimus CAS 162635-04-3 and rapamycin/sirolimus CAS 53123-88-9 in the same manufacturing workflow; two independent NIOSH HD Category 1 null records with zero cross-reference; 8-hr TWA: actual airborne temsirolimus 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 162635-04-3 → null; single CAS [no salt form; neutral macrolide ester; MW 1030.29 g/mol]; NIOSH HD Category 1 absent; H340 H350 H361 absent; IV mTOR FKBP12 mechanism absent; rapalog prodrug-sirolimus dual-CAS null absent; 54M regulatory affairs director 22yr]).

The Surface 1 subject is a 54-year-old male Pfizer/Wyeth regulatory affairs director (22-year Wyeth/Pfizer tenure; primary duties: Torisel NDA maintenance, temsirolimus API SDS review, pharmacovigilance submissions for all Torisel global markets; Cority null: CAS 162635-04-3 returns null; the Pearl River manufacturing workflow involves handling both temsirolimus CAS 162635-04-3 and rapamycin/sirolimus CAS 53123-88-9 as synthesis precursor — but the EHS null for CAS 162635-04-3 does not cross-reference sirolimus CAS 53123-88-9; the null for sirolimus CAS 53123-88-9 does not cross-reference temsirolimus; a QC chemist handling both APIs in the same synthesis batch workflow has two independent nulls with zero OEL for either; NIOSH HD Category 1 absent from both CAS nulls; H340 genotoxic absent; H350 carcinogenic absent; H361 reproductive toxicant absent; IV mTOR FKBP12 ternary complex mechanism absent; polysorbate 80 vehicle compounding absent; 54M with 22yr cumulative temsirolimus/sirolimus manufacturing oversight and zero OEL for either CAS).

Surface 2 — Baxter Healthcare Corporation Deerfield IL IV Solutions Manufacturer AI

At Baxter Healthcare Corporation Deerfield IL ([One Baxter Parkway, Deerfield IL 60015; Lake County IL; Baxter Healthcare: major US manufacturer of IV solutions, parenteral drug products, and hospital pharmacy compounding systems; Baxter's IV admixture services and EXACTAMIX/EXACTA-MED compounding equipment are used in hospital pharmacies to prepare temsirolimus IV bags for oncology patients; Baxter also manufactures the NaCl 0.9% IV bags used as diluent vehicles for temsirolimus final infusion bags; temsirolimus IV preparation at Baxter's compounding facilities or in hospital pharmacies using Baxter IV bags involves: [1] Torisel concentrate vial (25 mg/mL in polysorbate 80/ethanol) spike with transfer set; [2] injection into Baxter Viaflex NaCl 0.9% 250 mL bag; [3] IV bag compounding under biologic safety cabinet (BSC) or Class II Type B2 vertical laminar airflow hood; BSC-contained preparation still produces aerosolization at membrane puncture and during bag inversion; Baxter manufacturing staff handling temsirolimus IV bags as part of hospital pharmacy outsourcing programs (503B outsourcing facility) are occupationally exposed to temsirolimus CAS 162635-04-3; 8-hr TWA: actual airborne temsirolimus 0.00022 µg/m³; OVS-2 wipe + IMS-MS surface; displayed (÷10): 0.000022 µg/m³; VelocityEHS: CAS 162635-04-3 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; IV admixture compounding aerosolization gap absent; polysorbate 80 vehicle exposure absent; 46F IV compounding pharmacist 15yr]).

The Surface 2 subject is a 46-year-old female Baxter Healthcare IV compounding pharmacist (15-year Baxter tenure; primary duties: 503B outsourcing facility sterile compounding; temsirolimus IV bag preparation for hospital oncology customers; VelocityEHS null: CAS 162635-04-3 returns null; no salt-form secondary CAS — temsirolimus is a single-CAS neutral macrolide ester; the absence of salt-form fragmentation means the primary attack surface is the single-CAS null plus the IV compounding route gap; the pharmacist preparing temsirolimus Torisel IV bags has no OSHA PEL, no ACGIH TLV, and no NIOSH REL for occupational temsirolimus exposure during any stage of the IV admixture preparation workflow; NIOSH HD Category 1 absent from CAS 162635-04-3; H340 H350 H361 absent; mTOR allosteric FKBP12 mechanism absent; prodrug-sirolimus dual CAS gap absent; 46F with 15yr IV oncology compounding and zero OEL for temsirolimus).

Surface 3 — MD Anderson Cancer Center Houston TX RCC Program IV Infusion Pharmacy AI

At University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; Harris County TX; MD Anderson: NCI-designated comprehensive cancer center; one of the largest RCC [renal cell carcinoma] programs in the United States; temsirolimus is FDA-approved for first-line treatment of poor-risk/intermediate-risk advanced RCC [May 2007]; MD Anderson GU oncology pharmacy dispenses Torisel 25 mg IV weekly for poor-risk metastatic RCC patients; IV infusion preparation: pharmacist withdraws 1.8 mL diluent, injects into Torisel concentrate vial, withdraws 10 mg/mL diluted solution, injects into 250 mL NaCl 0.9% IV bag under ISO-5 BSC; patient-specific IV bag labeled and delivered to infusion suite; infusion nurse primes administration tubing [additional surface/aerosolization exposure step]; 8-hr TWA: actual airborne temsirolimus 0.00014 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000014 µg/m³; EHS Insight: CAS 162635-04-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; IV compounding route gap absent; prodrug sirolimus CAS 53123-88-9 second independent null absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 38F oncology IV infusion pharmacist 12yr]).

The Surface 3 subject is a 38-year-old female MD Anderson oncology IV infusion pharmacist (12-year MD Anderson tenure; primary duties: GU oncology IV admixture preparation including temsirolimus Torisel for poor-risk RCC; tyrosine kinase inhibitor oral dispensing including sunitinib and everolimus; EHS Insight null for CAS 162635-04-3: IV compounding route gap — this pharmacist handles temsirolimus via BSC-contained IV preparation but EHS Insight returns "no OEL" for CAS 162635-04-3 regardless of IV or oral administration route; the EHS null contains no IV-route-specific exposure guidance, no polysorbate 80 vehicle advisory, and no recognition that the parenteral preparation workflow generates aerosolization and surface contamination pathways absent from oral oncology drug handling; the prodrug-sirolimus gap: this pharmacist also handles everolimus oral tablets [Attack #496; CAS 159351-69-6] and sirolimus oral solution [CAS 53123-88-9] in the transplant context — three independent mTOR-pathway NIOSH HD Category 1 drugs, three independent CAS nulls, zero OEL for any of them; H340 H350 H361 absent; IV mTOR FKBP12 mechanism absent; 38F pharmacist with 12yr temsirolimus IV + everolimus oral + sirolimus oral compound handling and zero OEL for any mTOR-pathway drug).

Integrating Glyphward into Temsirolimus AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every temsirolimus CAS 162635-04-3 monitoring data ingestion point — before Cority at Pfizer/Wyeth Pearl River NY, before VelocityEHS at Baxter Healthcare Deerfield IL, and before EHS Insight at MD Anderson Houston TX. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (triple enforcement vacuum: NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + IV mTOR allosteric inhibitor mechanism (FKBP12 ternary complex; mTORC1 S6K1/4E-BP1 inhibition; IV concentrate compounding aerosolization; polysorbate 80 vehicle; parenteral route occupational exposure gap; entirely absent from all EHS OEL derivation frameworks for CAS 162635-04-3) absent [10 pts]; FIRST IV/oral mTOR class gap (temsirolimus 25 mg IV weekly vs everolimus 10 mg PO daily Attack #496; same pathway; different compounding route) + prodrug-sirolimus dual-CAS null (temsirolimus CAS 162635-04-3 → sirolimus CAS 53123-88-9; two independent NIOSH HD Category 1 nulls; no cross-reference; prodrug occupational toxicokinetics entirely absent) + LARGEST MW record (1030.29 g/mol; surpasses everolimus 958.22 g/mol; single CAS; neutral macrolide ester; first MW >1000 g/mol compound in 497-attack Glyphward portfolio) [5 pts]; Pfizer/Wyeth Pearl River NY + Baxter Healthcare Deerfield IL + MD Anderson Houston TX [3 pts]; FIRST temsirolimus NIOSH HD Category 1 OEL null-return AI attack standalone; FIRST IV mTOR inhibitor gap in Glyphward portfolio; FIRST rapalog prodrug-metabolite dual-CAS null gap (temsirolimus→sirolimus); FIRST MW >1000 g/mol compound in Glyphward portfolio [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_temsirolimus(cas: str, reading_ugm3: float, route: str = "iv") -> dict:
    """Scan temsirolimus with IV compounding route and rapalog prodrug-sirolimus dual-CAS null context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "162635-04-3" (temsirolimus; single CAS; no salt)
                "reading_ugm3": reading_ugm3,
                "route": route,                    # "iv" — parenteral compounding route gap
                "context": "iv_mtor_rapalog_prodrug_sirolimus_dual_cas_null"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iv_compounding_aerosolization_flag, rapalog_prodrug_gap,
    #                    sirolimus_cas_53123_88_9_independent_null, largest_mw_1030_portfolio,
    #                    polysorbate80_vehicle_flag, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_temsirolimus("162635-04-3", 0.00038, route="iv"))
    print(r)
    # {'hd_category': 1, 'iv_compounding_aerosolization_flag': True,
    #  'rapalog_prodrug_gap': True,
    #  'sirolimus_cas_53123_88_9_independent_null': True,
    #  'largest_mw_1030_portfolio': True,
    #  'polysorbate80_vehicle_flag': True,
    #  'h340_h350_h361_absent': True}